Continuous Manufacturing On Horizon As Competitive Edge In OTC Space
This article was originally published in The Tan Sheet
While OTC firms’ slimmer profit margins make equipment changes or other capital investments more difficult for them than for Rx firms, continuous manufacturing will be worth the investment, says CDER Director Janet Woodcock. “We’re going to see a lot of these out there,” she says.
You may also be interested in...
So full of errors were the firm's online ads for its Plavinol supplement, the National Advertising Division noted support for some claims contained "many of the same flaws" as others. The prevalence of problems prompted NAD to go outside its "scope of review" and note unclear instructions on Plavinol labels.
Perrigo "walked away a little bit" from "a model that worked beautifully," says CEO Murray Kessler at investor conference, "In essence, all we've done over the last year is to put back in place the model that worked so well."